ATE290862T1 - Anti-androgene und verfahren zur behandlung von krankheiten - Google Patents
Anti-androgene und verfahren zur behandlung von krankheitenInfo
- Publication number
- ATE290862T1 ATE290862T1 AT00905748T AT00905748T ATE290862T1 AT E290862 T1 ATE290862 T1 AT E290862T1 AT 00905748 T AT00905748 T AT 00905748T AT 00905748 T AT00905748 T AT 00905748T AT E290862 T1 ATE290862 T1 AT E290862T1
- Authority
- AT
- Austria
- Prior art keywords
- androgens
- methods
- treating diseases
- diseases
- gonadotropins
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000051 antiandrogen Substances 0.000 title 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 title 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 102000006771 Gonadotropins Human genes 0.000 abstract 1
- 108010086677 Gonadotropins Proteins 0.000 abstract 1
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 abstract 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 229940030486 androgens Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002622 gonadotropin Substances 0.000 abstract 1
- 229940094892 gonadotropins Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11705999P | 1999-01-25 | 1999-01-25 | |
| PCT/US2000/001956 WO2000043008A1 (en) | 1999-01-25 | 2000-01-25 | Anti-androgens and methods for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290862T1 true ATE290862T1 (de) | 2005-04-15 |
Family
ID=22370778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00905748T ATE290862T1 (de) | 1999-01-25 | 2000-01-25 | Anti-androgene und verfahren zur behandlung von krankheiten |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1146873B1 (de) |
| JP (1) | JP2002535274A (de) |
| AT (1) | ATE290862T1 (de) |
| DE (1) | DE60018707T2 (de) |
| ES (1) | ES2237408T3 (de) |
| WO (1) | WO2000043008A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002259147A1 (en) | 2001-05-08 | 2002-11-18 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
| TWI329108B (en) | 2001-09-06 | 2010-08-21 | Schering Corp | 17-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| AR036812A1 (es) | 2001-10-17 | 2004-10-06 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| MX342161B (es) | 2010-04-02 | 2016-09-19 | Euroscreen Sa | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. |
| CN103906750B9 (zh) | 2011-10-03 | 2016-10-12 | 欧洲筛选有限公司 | 作为选择性NK-3受体拮抗剂的新型手性N-酰基-5,6,7,(8-取代的)-四氢-[1，2,4]三唑并[4，3-a]吡嗪、药物组合物、用于NK-3受体介导的疾病中的方法及其手性合成 |
| CA2907813C (en) | 2013-03-29 | 2021-09-07 | Euroscreen Sa | Novel n-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
| CA2907814C (en) | 2013-03-29 | 2021-07-13 | Euroscreen Sa | Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| ES2646488T3 (es) | 2013-03-29 | 2017-12-14 | Ogeda S.A. | N-acil-(3-sustituido)-(8-sustituido)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para uso en trastornos mediados por el receptor NK-3 |
| CA2909752A1 (en) | 2013-04-19 | 2014-10-23 | Astrazeneca Ab | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
| GB201315846D0 (en) | 2013-09-05 | 2013-10-23 | Imp Innovations Ltd | Method for treating or preventing hot flushes |
| EP3271015B8 (de) * | 2015-03-16 | 2023-11-01 | Ogeda N.V. | Nk-3-rezeptorantagonisten zur therapeutischen oder kosmetischen behandlung von übermässigem körperfett |
| JP6902682B2 (ja) * | 2015-05-18 | 2021-07-14 | カンディー セラピューティクス リミテッド | 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト |
| WO2017072629A1 (en) * | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| MX2023001199A (es) * | 2020-07-30 | 2023-03-13 | Acer Therapeutics Inc | Antagonistas de receptor nk para pacientes con cancer. |
| TW202317533A (zh) | 2021-07-02 | 2023-05-01 | 美商雅斯治療公司 | 奧沙奈坦(osanetant)之固體形式 |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120840A (en) * | 1990-08-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | 4-amino-4-ene-steroids and their use as 5α-reductase inhibitors |
| SK140494A3 (en) * | 1992-05-21 | 1995-07-11 | Endorecherche Inc | Inhibitors of testosterone 5-alpha-reductase activity |
| GB9216329D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives |
| US5380728A (en) * | 1993-02-10 | 1995-01-10 | Merck & Co., Inc. | Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a |
| ES2227769T3 (es) * | 1994-05-27 | 2005-04-01 | Glaxosmithkline S.P.A. | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. |
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| IT1275594B1 (it) * | 1995-07-21 | 1997-08-06 | Pharmacia S P A Ora Pharmacia | Epimeri del (22rs)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-osso -4-aza-5alfa-androst-1-ene-17beta-carbossammide |
-
2000
- 2000-01-25 EP EP00905748A patent/EP1146873B1/de not_active Expired - Lifetime
- 2000-01-25 ES ES00905748T patent/ES2237408T3/es not_active Expired - Lifetime
- 2000-01-25 AT AT00905748T patent/ATE290862T1/de not_active IP Right Cessation
- 2000-01-25 WO PCT/US2000/001956 patent/WO2000043008A1/en not_active Ceased
- 2000-01-25 DE DE60018707T patent/DE60018707T2/de not_active Expired - Fee Related
- 2000-01-25 JP JP2000594462A patent/JP2002535274A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE60018707D1 (de) | 2005-04-21 |
| JP2002535274A (ja) | 2002-10-22 |
| WO2000043008A1 (en) | 2000-07-27 |
| EP1146873A4 (de) | 2003-03-26 |
| EP1146873B1 (de) | 2005-03-16 |
| ES2237408T3 (es) | 2005-08-01 |
| DE60018707T2 (de) | 2006-02-09 |
| EP1146873A1 (de) | 2001-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290862T1 (de) | Anti-androgene und verfahren zur behandlung von krankheiten | |
| ATE208210T1 (de) | Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs | |
| ATE313326T1 (de) | VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| ATE360417T1 (de) | Methode zur behandlung von zytokinvermittelten erkrankungen | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| ATE267013T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
| DE60228583D1 (de) | Verfahren und materialien für die behandlung des testosteron-mangels bei männern | |
| DE60312474D1 (de) | 5-ht3-rezeptorantagonisten und verwendungsverfahren | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE60220385D1 (de) | Benzimidazole zur behandlung sexueller fehlfunktionen | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| DE602004007672D1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| ATE337787T1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
| DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE385789T1 (de) | Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen | |
| DE60219658D1 (de) | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE476987T1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
| MXPA04000805A (es) | Peptidos que tienen actividad antiangiogenica. | |
| DE60209886D1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |